High absorption cream is an industry first, meeting patient needs
MARKHAM, ON, Oct. 4, 2017 /CNW/ - MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified producer of medical cannabis, today announced the launch of a topical cream, the first Canadian Licensed Producer to do so. The cream is specifically formulated to provide superior absorption with MedReleaf's award-winning high CBD strain and was developed in response to patient feedback for topical applications of CBD. MedReleaf Topical Cream mixes and integrates with the cannabis oil to create an easy-to-use topical agent for direct application to affected areas.
"Our product development team has devised a method to provide Canadian patients with a much sought-after, high-absorption, topical cream that is within the strict limitations afforded by the current regulations," said Neil Closner, CEO of MedReleaf. "This is further evidence of MedReleaf's continued leadership in setting the standard for product innovation and focus on the patient experience."
"The Dermatology community is very intrigued and excited about the potential benefits of cannabinoids including Cannabidiol (CBD) in treating a variety of skin ailments," said Dr. Jaggi Rao, MD, Board Certified Dermatologist, and Clinical Professor of Medicine at the University of Alberta. "These novel agents could offer significant relief to patients suffering from pain and itch in a number of inflammatory dermatoses. They have already demonstrated anti-inflammatory benefits in muscle and joint disorders, and the translation of this success to skin diseases is only logical."
Topicals are seeing strong growth in US markets with a tripling of sales since 2014 and forecasts indicating a further tripling of sales by 2019, according to the Brightfield Group. MedReleaf's topical cream uses cosmetic grade ingredients; is approved by Health Canada for sale; and is currently available at a special introductory price to allow as many patients as possible to experience this exciting new product. The suggested concentration of cannabis in MedReleaf's mixed lotion is substantially more than any equivalent products currently available in the US market. Easy to follow instructions are included to allow for easy mixing of the cream with our cannabis oil in order to enable use almost immediately. The product is available now. Visit medreleaf.com/cream for more information.
About MedReleaf Corp.
MedReleaf sets The Medical Grade Standard™ for cannabis in Canada and around the world. The first and only ICH-GMP and ISO 9001 certified cannabis producer in North America, MedReleaf is a R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis. Sourced from around the world and perfected in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis.
For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleaf
Forward Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which are based upon MedReleaf's current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact.
Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, MedReleaf does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for MedReleaf to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in MedReleaf's Annual Information Form dated June 27, 2017 and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in MedReleaf's Annual Information Form could cause actual events or results to differ materially from those described in any forward-looking information.
SOURCE MedReleaf Corp.
For further information: Dennis Fong, Investor Relations, email@example.com, 416-283-9930